EU Looks At New Ways To Boost Third-Country API Safety
Adequacy Of 'Written Confirmation' Policy Is In Doubt
Executive Summary
The EU is working on new measures to ensure the safety of active substances imported from third countries, suggesting that the current system of requiring written notifications is not fit for purpose. The move follows recent cases of nitrosamine contamination in medicines containing imported APIs.
You may also be interested in...
Nitrosamine Episode Could Lead To Paradigm Shift In Quality
The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.
US, EU Hit Inspection Deal Milestone; Batch Test Waiver Kicks In
After 20 years in the making, the landmark GMP inspection MRA between the US and the EU is finally fully implemented. In addition, a batch test waiver has started to apply under the deal.
South Korea Passes EU's GMP Equivalence Assessment For APIs
The European Commission took four years to evaluate South Korea's regulatory framework for active pharmaceutical ingredients and to conclude that it is in line with EU standards.